Study backs pneumatic compression method:
This article was originally published in Clinica
Executive Summary
The first prospective study to evaluate intermittent pneumatic compression (IPC) as an adjunctive treatment for breast cancer-associated lymphedoema (fluid accumulation) has found it to be safe and effective. The study, conducted by researchers at the Stanford University School of Medicine, California, assessed the technique in 27 patients with lymphedoema as a consequence of surgery and radiation to treat breast cancer. Used alongside other, established decongestive lymphatic therapy, IPC provides an enhancement of patients' therapeutic response, say the researchers, whose findings appear in Cancer (December 1).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.